CD19-targeted Chimeric Antigen Receptor (CAR) T Cells

BIOLOGICAL3 trials

Sponsors

Shanghai Ming Ju Biotechnology Co., Ltd.

Conditions

Acute Lymphocytic LeukemiaDiffuse Large B Cell LymphomaFollicular LymphomaLymphoma, Non-HodgkinMantle Cell Lymphoma

Phase 1

CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia

Shanghai Ming Ju Biotechnology Co., Ltd.Acute Lymphocytic Leukemia

Start: 2022-04-28End: 2025-07-31Target: 33Updated: 2023-02-14

Phase 2

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

Shanghai Ming Ju Biotechnology Co., Ltd.Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin

Start: 2019-06-11End: 2024-09-30Target: 82Updated: 2023-11-24

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Active, not recruitingNCT04718883

Shanghai Ming Ju Biotechnology Co., Ltd.Mantle Cell Lymphoma

Start: 2021-01-13End: 2028-08-07Updated: 2023-11-24

Related Papers

Two‐year follow‐up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in <scp>RELIANCE</scp> study

British Journal of Haematology2025-09-01

Phase 2 Study of Relmacabtagene Autoleucel (CD19 CAR-T) for Relapsed/Refractory Mantle Cell Lymphoma in Chinese Adults

Blood Advances2025-08-141 citations

Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching‐Adjusted Indirect Analysis

Hematological Oncology2025-03-01

Long-term survival outcomes in patients with relapsed/refractory large B-cell lymphoma after treatment of relma-cel: 4-year follow-up in RELIANCE study.

Journal of Clinical Oncology2024-06-01

Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL): Updated Results from a Phase II Open-Label Study in China

Blood2023-11-021 citations

Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: Updated results of the RELIANCE study.

2023-02-2415 citations

Preliminary Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) in China

Blood2022-11-152 citations

Two-year follow-up result of RELIANCE study, a multicenter phase 2 trial of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma.

Journal of Clinical Oncology2022-06-013 citations

Relma-cel (JWCAR029) in relapsed and refractory B-cell non-Hodgkin lymphoma: A two-year survival update of a phase I study.

Journal of Clinical Oncology2022-06-012 citations

Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) as second-line therapy for primary refractory Chinese patients with large B-cell lymphoma (LBCL): Results from an open-label, multicenter, single-arm phase I study.

Journal of Clinical Oncology2022-06-011 citations

Relmacabtagene Autoleucel CD19 CART Therapy for Adults with Heavily-Pretreated Relapsed/Refractory Large B-Cell Lymphoma in China

Blood2021-11-054 citations

Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China

Cancer Medicine2020-12-3198 citations